Lilly Q2 revenue up 48% to $23.0B; raises full-year guidance

ELI LILLY & Co

Q2 2026 revenue $22,974M (+48% YoY); reported EPS $7.94 (+26%), non-GAAP EPS $8.38 (+33%).
Full-year revenue guidance raised to $85.0-87.0B; non-GAAP EPS guidance $35.50-$36.50 (up $2.78 midpoint).
Q2 EPS includes $3.03/share of acquired IPR&D charges from business development activity.
Completed acquisitions of Orna, Ajax, Centessa, Kelonia; post-quarter added infectious disease assets and AtaiBeckley.
Committed $4.5B to expand Indiana manufacturing sites; retatrutide Phase 3 data complete for global registrations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.